Insulin Glargine
Drug #1751
Insulin Glargine is a recombinant human insulin analogue. It is used in the treatment of diabetes mellitus. It is a long-acting insulin.
Primary Characteristics
Non-proprietary name: Insulin Glargine.
Pharmacokinetics
None recorded.
Advertisement
Indications
Insulin Glargine is primarily indicated in conditions like Type I diabetes mellitus, Type II diabetes mellitus.
Contraindications
Insulin Glargine is contraindicated in conditions like Hypersensitivity to the drug.
Dosage
Insulin Glargine's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 10 units/day | 10 units/day | — | SC | For type 2 diabetes: Initial dose: |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
None recorded.
Side Effects
Insulin Glargine is known to cause more or less tolerable side effects which are usually transient. These include Allergic reactions, Fat hypertrophy at injection site, Hypoglycemia, Local reactions.
Warnings / Precautions
Insulin Glargine should be used with caution in patients with renal impairment (May need dose reduction). COUNSELLING: Show container to patient and confirm that patient is expecting the version dispensed.
It is not intended for intravenous administration. The prolonged duration of activity of insulin glargine is dependent on injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycemia.
Interference in Pathology
Insulin Glargine may interfere in the diagnosis of Monitoring of blood and urine glucose.
Available Brands
Drug Classification
- 1.18.7.1 — Insulins